Teva presents new data on investigational olanzapine LAI and UZEDY

Teva presented new data on investigational Olanzapine long-acting injectable (LAI) and UZEDY at Psych Congress 2026 (Sept. 15–19, N…). The treatments use Medincell’s BEPO technology licensed to Teva as SteadyTeq.